[go: up one dir, main page]

MX2023000150A - Compuesto de sulfonamida. - Google Patents

Compuesto de sulfonamida.

Info

Publication number
MX2023000150A
MX2023000150A MX2023000150A MX2023000150A MX2023000150A MX 2023000150 A MX2023000150 A MX 2023000150A MX 2023000150 A MX2023000150 A MX 2023000150A MX 2023000150 A MX2023000150 A MX 2023000150A MX 2023000150 A MX2023000150 A MX 2023000150A
Authority
MX
Mexico
Prior art keywords
compounds
sulphonamide compounds
formula
sulphonamide
mlkl
Prior art date
Application number
MX2023000150A
Other languages
English (en)
Inventor
John Thomas Feutrill
Jean- Marc Daniel GARNIER
Martin Brzozowski
Guillaume Laurent Lessene
Christopher Gardner
Peter Edward Czabotar
Angus Cowan
Katherine Davies
Pooja Sharma
Carole Annie Schuster-Klein
Christophe Poitevin
Original Assignee
Anaxis Pharma Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2020902035A external-priority patent/AU2020902035A0/en
Application filed by Anaxis Pharma Pty Ltd filed Critical Anaxis Pharma Pty Ltd
Publication of MX2023000150A publication Critical patent/MX2023000150A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Epidemiology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La presente invención se refiere a compuestos de la fórmula (I) y sales, solvatos, tautómeros, N-óxidos, estereoisómeros, polimorfos y/o profármacos de los mismos. También se divulga el uso de los compuestos de la fórmula (I) para tratar la necroptosis y/o inhibir MLKL.
MX2023000150A 2020-06-19 2021-06-18 Compuesto de sulfonamida. MX2023000150A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2020902035A AU2020902035A0 (en) 2020-06-19 Sulphonamide compounds
PCT/AU2021/050638 WO2021253095A1 (en) 2020-06-19 2021-06-18 Sulphonamide compounds

Publications (1)

Publication Number Publication Date
MX2023000150A true MX2023000150A (es) 2023-03-22

Family

ID=79268755

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023000150A MX2023000150A (es) 2020-06-19 2021-06-18 Compuesto de sulfonamida.

Country Status (10)

Country Link
US (1) US20230227429A1 (es)
EP (1) EP4168401B1 (es)
JP (1) JP7769648B2 (es)
KR (1) KR20230043103A (es)
CN (1) CN115956070A (es)
AU (1) AU2021294035A1 (es)
BR (1) BR112022025732A2 (es)
CA (1) CA3182873A1 (es)
MX (1) MX2023000150A (es)
WO (1) WO2021253095A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL308759A (en) 2021-05-27 2024-01-01 Boundless Bio Inc Checkpoint kinase 1 (CHK1) inhibitors and uses thereof
CA3241624A1 (en) * 2021-12-22 2023-06-29 Anaxis Pharma Pty Ltd Arylsulphonamide compounds
JP2025501766A (ja) * 2021-12-22 2025-01-23 アナシス・ファルマ・プロプライエタリー・リミテッド 二官能性アリールスルホンアミド化合物
EP4452966A4 (en) * 2021-12-22 2025-12-17 Anaxis Pharma Pty Ltd BIFUNCTIONAL SULFONAMIDE COMPOUNDS

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100353014B1 (ko) * 1998-11-11 2002-09-18 동아제약 주식회사 발기부전 치료에 효과를 갖는 피라졸로피리미디논 화합물
CA2476281A1 (en) 2002-02-08 2003-08-14 Smithkline Beecham Corporation Pyrimidine compounds
US20120122889A1 (en) * 2008-12-23 2012-05-17 President And Fellows Of Harvard College Small molecule inhibitors of necroptosis
EP2882741B1 (en) * 2012-08-10 2018-10-24 Boehringer Ingelheim International GmbH Heteroaromatic compounds as bruton's tyrosine kinase (btk) inhibitors
CN103520162B (zh) * 2013-10-15 2015-11-18 中国科学院上海药物研究所 达拉菲尼抑制程序性坏死和保护肝脏的应用
BR112016026544A2 (pt) * 2014-05-15 2017-12-12 Catalyst Therapeutics Pty Ltd métodos para inibir a necroptose
EP3256452A1 (en) * 2015-02-10 2017-12-20 Catalyst Therapeutics Pty Ltd. Inhibitors of necroptosis
US11072607B2 (en) * 2016-12-16 2021-07-27 Genentech, Inc. Inhibitors of RIP1 kinase and methods of use thereof
WO2018192416A1 (en) * 2017-04-17 2018-10-25 National Institute Of Biological Sciences, Beijing Treating Male Senescence

Also Published As

Publication number Publication date
JP2023530011A (ja) 2023-07-12
CN115956070A (zh) 2023-04-11
AU2021294035A1 (en) 2023-02-16
JP7769648B2 (ja) 2025-11-13
BR112022025732A2 (pt) 2023-03-07
EP4168401A1 (en) 2023-04-26
EP4168401B1 (en) 2026-01-07
WO2021253095A1 (en) 2021-12-23
CA3182873A1 (en) 2021-12-23
KR20230043103A (ko) 2023-03-30
EP4168401A4 (en) 2024-07-17
US20230227429A1 (en) 2023-07-20

Similar Documents

Publication Publication Date Title
MX2023000150A (es) Compuesto de sulfonamida.
MX2024007887A (es) Compuestos de arilsulfonamida bifuncionales.
MX2020004699A (es) Derivados de pirimidina como inhibidores de la activacion de pd1/pd-l1.
MX390287B (es) Composiciones farmacéuticas que contienen derivados de piridona policíclicos sustituidos y profármacos de los mismos.
UY37847A (es) Sulfonilureas y sulfoniltioureas útiles como inhibidores de nlrp3
MX2022000939A (es) Compuestos macrocíclicos como agonistas de sting y métodos y usos de los mismos.
AR113688A1 (es) Proceso para la preparación de compuestos de piridiminio ópticamente activo
MX2022010040A (es) Compuestos moduladores de gcn2.
CL2022001950A1 (es) Compuestos de sulfonimidamida como moduladores de nlrp3.
AR105238A1 (es) Compuestos de benzoxacepina oxazolidinona y métodos de uso
UY31940A (es) Derivados sustituido del 4,5-(sustituido-piridin-3-il)-1-metil-1h-indol, sus sales farmacéuticamente aceptables, polimorfos, rotámeros, pro-fármacos, anantiómeros, hidratos, solvatos del mismo, composiciones conteniéndolos y aplicaciones
UY26727A1 (es) Derivados de tropano útiles en terapia
DOP2021000017A (es) Compuestos de pirimidina y composiciones farmaceuticas para prevenir o tratar cánceres que incluyen los mismos
ECSP088286A (es) COMPUESTOS DE AMINO-5-[4-(DIFLUOROMETOXI)FENIL]-5-FENILIMIDAZOLONA PARA LA INHIBICIÓN DE LA ß-SECRETASA
DOP2020000222A (es) Derivado policiclico de piridona
AR133968A1 (es) Nuevo compuesto derivado de ftalazina como inhibidor de sos1 y uso del mismo
CL2021000443A1 (es) Compuestos de sulfonamida sustituidos con heteroarilo y su uso como agentes terapéuticos.
AR124868A1 (es) Compuestos de heterociclo tetracíclicos útiles como inhibidores de la integrasa del vih
CO2019005514A2 (es) Derivado de pirido[3,4–d]pirimidina y su sal farmacéuticamente aceptable
UY37647A (es) Amidas de ácido n–(1,3,4–oxadiazol–2–il)arilcarboxílico sustituidas y su compuesto como herbicidas
CL2021002480A1 (es) Agonistas compuestos macrocíclicos como de sting
MX389378B (es) Derivados de amino-imidazopiridina novedosos como inhibidores de cinasa de janus y uso farmacéutico de estos.
DOP2025000064A (es) Proceso para la preparación de un agente de contraste de gadolinio
MX2024007883A (es) Compuestos de sulfonamida bifuncionales.
CU20250003A7 (es) Compuestos de piridinona sustituida como inhibidores de cbl-b